TI
ARCT icon

Trexquant Investment’s Arcturus Therapeutics ARCT Stock Holding History

Trexquant Investment’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-74,424
Closed -$1.73M – 1539
2024
Q3 		$1.73M Buy
74,424
+21,015
+39% +$450K 0.02% 868
2024
Q2 		$1.3M Buy
+53,409
New +$1.62M 0.02% 912
2024
Q1 		– Sell
-10,956
Closed -$345K – 1419
2023
Q4 		$345K Sell
10,956
-40,915
-79% -$972K 0.01% 1210
2023
Q3 		$1.33M Buy
51,871
+17,230
+50% +$531K 0.03% 642
2023
Q2 		$994K Buy
+34,641
New +$943K 0.03% 762
2023
Q1 		– Sell
-21,284
Closed -$361K – 1424
2022
Q4 		$361K Buy
+21,284
New +$371K 0.01% 1040
2022
Q1 		– Sell
-5,939
Closed -$220K – 1330
2021
Q4 		$220K Buy
+5,939
New +$242K 0.01% 1100
2021
Q2 		– Sell
-5,428
Closed -$224K – 1076
2021
Q1 		$224K Buy
+5,428
New +$324K 0.02% 916
2020
Q2 		– Sell
-12,632
Closed -$172K – 1150
2020
Q1 		$172K Buy
+12,632
New +$162K 0.01% 997

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Trexquant Investment's ARCT Position: Q4 2024 in Review

Trexquant Investment sold out of Arcturus Therapeutics (ARCT) in Q4 2024, closing a stake of 74,424 shares — an estimated $1.73M sold.

Trexquant Investment first reported a position in ARCT in Q1 2020 and held it in 9 quarters. The position peaked at $1.73M in Q3 2024. 147 funds tracked by Wall St. Rank hold ARCT as of Q4 2024.

  • Trexquant Investment reported no remaining Arcturus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Trexquant Investment sold 74,424 Arcturus Therapeutics shares in Q4 2024, an estimated $1.73M.
  • Trexquant Investment first reported a position in Arcturus Therapeutics in Q1 2020 and held it in 9 quarters.
  • Trexquant Investment's Arcturus Therapeutics position peaked at $1.73M in Q3 2024.
  • 147 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2024.

Based on Trexquant Investment's 13F filing for Q4 2024, filed 12 Feb 2025.